You are on page 1of 2

38088 Federal Register / Vol. 72, No.

133 / Thursday, July 12, 2007 / Notices

inhibitors that are indicated for the DEPARTMENT OF HEALTH AND opportunity to pursue this therapeutic
treatment of cocaine abuse and ADHD. HUMAN SERVICES strategy.
They bind with high affinity to the Applications: Applicable as anti-
dopamine transporter and block National Institutes of Health cancer therapeutics for a wide variety of
dopamine uptake, but generally do not tumors, including breast cancer, ovarian
Government-Owned Inventions; cancer, and neuroblastomas. Inhibitors
produce behavioral effects comparable
Availability for Licensing can also be combined with other cancer
to those produced by cocaine. In animal
models of drug abuse, many benztropine AGENCY: National Institutes of Health, therapeutics.
Public Health Service, HHS. Advantages: Inhibitors are designed
analogs have been shown to (1) Reduce
based on strucural similarity to the
cocaine-induced locomotor stimulation, ACTION: Notice.
native substrate, providing a high degree
(2) have long-lasting effects, and (3) lack of specificity to the target. First
a significant abuse liability. This SUMMARY: The inventions listed below
are owned by an agency of the U.S. inhibitors directed to Wip1 as a target
suggests they may be useful medications for cancer therapy.
for the treatment of human diseases Government and are available for
licensing in the U.S. in accordance with Benefits: Cancer is the second leading
where dopamine-related behavior is cause of death in the United States, with
compromised, especially in situations in 35 U.S.C. 207 to achieve expeditious
commercialization of results of federally approximately 600,000 cancer-related
which an (partial) agonist treatment is deaths occurring in 2006 alone. Wip1
funded research and development.
indicated. inhibitors may provide a social benefit
Foreign patent applications are filed on
However, some of the reported selected inventions to extend market by reducing that number or improving
analogs have limited or poor solubility coverage for companies and may also be the quality/length of patient life.
in aqueous systems or poor stability available for licensing. Furthermore, the cancer therapeutic
characteristics. To remedy this, the 3- market is expected to reach $27 billion
ADDRESSES: Licensing information and
position benzhydrylether moiety of the by 2009. Because these molecules are
copies of the U.S. patent applications the first inhibitors of Wip1, there is an
benztropine analogs was replaced with listed below may be obtained by writing opportunity to occupy a significant
the isosteric benzhydrylamine system in to the indicated licensing contact at the niche in that predicted market.
order to reduce hydrolysis of the less Office of Technology Transfer, National Inventors: Ettore Appella et al. (NCI).
stable ether function, observed in the Institutes of Health, 6011 Executive U.S. Patent Status: U.S. Provisional
benztropine series, and further reduce Boulevard, Suite 325, Rockville, Application No. 60/850,218 (HHS
lipophilicity to ultimately increase Maryland 20852–3804; telephone: 301/ Reference No. E–288–2006/0–US–01).
water solubility and bioavailability for 496–7057; fax: 301/402–0220. A signed Licensing Contact: David A.
improved therapeutic formulation and Confidential Disclosure Agreement will Lambertson, Ph.D.; Phone: (301) 435–
utility. be required to receive copies of the 4632; E-mail:
patent applications. lambertsond@mail.nih.gov.
Inventors: Amy H. Newman et al.
(NIDA). Cyclic Phosphopeptide Inhibitors of Collaborative Research Opportunity:
Protein Phosphatase 2C Delta, Wip1 The National Cancer Institute Center for
Publication: P Grundt; TA Kopajtic, JL Cancer Research, Laboratory for Cell
Katz, AH Newman. N–8–substituted- Description of Technology: This Biology, is seeking statements of
benztropinamine analogs as selective technology involves the development of capability or interest from parties
dopamine transporter ligands. Bioorg specific peptides that can be used as interested in collaborative research to
Med Chem Lett. 2005 Dec anti-cancer agents, particularly as further develop, evaluate, or
15;15(24):5419–5423. promoters of apoptosis. The inventors commercialize Cyclic Phosphopeptide
have modified the natural substrate of Inhibitors of Protein Phosphatase 2C
Patent Status: U.S. Provisional
the Wip1 protein phosphatase in order Delta, Wip1. Please contact John D.
Application No. 60/689,746 filed 10 Jun
to produce the inhibitors, allowing for Hewes, Ph.D. at 301/435–3121 or
2005 (HHS Reference No. E–089–2005/ specific and efficient inhibition of
0–US–01); International Application No. hewesj@mail.nih.gov for more
Wip1. These peptides represent the first information.
PCT/US2006/22401 filed 07 Jun 2006, Wip1 peptide inhibitors. The inhibitors
which published as WO 2006/135715 can be combined with other pro- A Gene Therapy to Treat Lung Cancer
on 21 Dec 2006 (HHS Reference No. E– apoptosis therapeutics to improve Description of Technology: This
089–2005/0–PCT–02). patient survival, providing an advantage invention relates to the identification of
Licensing Status: Available for to previous pro-apoptosis approaches. a new tumor suppressor gene named
exclusive or non-exclusive licensing. Wip1 (PP2Cdelta or PPM1D) is a Caliban from Drosophila melanogaster
protein phosphatase that negatively and Serologically determined colon
Licensing Contact: Tara L. Kirby,
regulates cell-cycle arrest and apoptosis cancer antigen gene 1 (Sdccag1) from
Ph.D.; 301/435–4426;
by preventing p53-mediated cell-cycle humans. Sdccag1 is inactive in human
tarak@mail.nih.gov arrest and apoptosis. Wip1 is lung cancer cells but active in normal
Dated: July 5, 2007. overexpressed in several human lung cells. When full length Caliban or
Steven M. Ferguson, cancers, including breast cancer, Sdccag1 is expressed in human lung
Director, Division of Technology Development ovarian clear cell adenocarcinoma and cancer cells they lose their
and Transfer, Office of Technology Transfer, neuroblastoma, suggesting it may play tumorigenicity. This suggests that
National Institutes of Health. an important role in oncogenesis. Caliban/Sdccag1 could be used as both
Inhibiting Wip1 may be a necessary step a therapeutic and diagnostic for cancer.
rwilkins on PROD1PC63 with NOTICES

[FR Doc. E7–13541 Filed 7–11–07; 8:45 am]


for inducing apoptosis and prohibiting Applications: Using gene therapy to
BILLING CODE 4140–01–P
tumor growth, accentuating the need for replace the inactive gene with full
Wip1-directed therapies. Because these length Caliban/Sdccag1 to treat
peptide inhibitors are the first specific cancer(s); A diagnostic assay that can
Wip1 inhibitors, they represent the first determine whether the tumor

VerDate Aug<31>2005 16:42 Jul 11, 2007 Jkt 211001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\12JYN1.SGM 12JYN1
Federal Register / Vol. 72, No. 133 / Thursday, July 12, 2007 / Notices 38089

suppressor Caliban/Sdccag1 gene individuals associated with the grant information concerning individuals
product is functioning in cells. applications, the disclosure of which associated with the proposed research
Advantages: Caliban/Sdccag1 can be would constitute a clearly unwarranted projects, the disclosure of which would
easily adopted into already standard invasion of personal privacy. constitute a clearly unwarranted
gene therapy applications; Provides a Name of Committee: National Human invasion of personal privacy.
novel therapeutic and diagnostic target Genome Research Institute Special Emphasis Name of Committee: Type 1 Diabetes—
for cancer. Panel, GWA Phenotype and Exposure Rapid Access to Intervention Development
Benefits: It is estimated that there will Measures. Special Emphasis Panel, National Institute of
be approximately 160,000 deaths caused Date: July 19, 2007. Diabetes and Digestive and Kidney Diseases.
by lung cancer in 2007. This technology Time: 12 p.m. to 1:30 p.m. Date: July 31, 2007.
will help in improving the quality of life Agenda: To review and evaluate grant Time: 12 p.m. to 2 p.m.
applications. Agenda: To evaluate requests for
of lung cancer patients as well as other
Place: National Institutes of Health, 5635 preclinical development resources for
cancers. Additionally, the gene therapy Fishers Lane, Suite 4076, Bethesda, MD potential new therapeutics for type 1 diabetes
market is now a multi-million dollar 20892 (Telephone Conference Call). and its complications.
industry. Contact Person: Ken D. Nakamura, PhD, Place: 6707 Democracy Boulevard,
Inventors: Mark A. Mortin (NICHD), Scientific Review Administrator, Scientific Bethesda, MD 20892 (Telephone Conference
Xiaolin Bi (NCI). Review Branch, National Human Genome Call).
U.S. Patent Status: Pending PCT Research Institute, National Institutes of Contact Person: Dr. Lisa Spain, Program
Application PCT/US2006/022180, Health, 5635 Fishers Lane, Suite 4076, MSC Director, Immunobiology of Type 1 Diabetes
published as WO 2006/13316 (E–118– 9306, Rockville, MD 20852, 301–402–0838, and Autoimmune Endocrine Diseases,
nakamurk@mail.nih.gov. Division of Diabetes, Endocrinology and
2005/0–PCT–02). This note is being published less than 15
Licensing Contact: David A. Metabolic Diseases, NIDDK, NIH, 6707
days prior to the meeting due to the timing Democracy Boulevard, Bethesda, MD 20892–
Lambertson, Ph.D.; Phone: (301) 435– limitations imposed by the review and 5460, 301–451–9871.
4632; Fax: (301) 402–0220; E-mail: funding cycle. (Catalogue of Federal Domestic Assistance
lambertsond@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes,
Collaborative Research Opportunity: Program Nos. 93.172, Human Genome Endocrinology and Metabolic Research;
The National Institute of Child Health Research, National Institutes of Health, HHS) 93.848, Digestive Diseases and Nutrition
and Human Development is seeking Dated: July 6, 2007. Research; 98.849, Kidney Diseases, Urology
statements of capability or interest from Jennifer Spaeth, and Hematology Research, National Institutes
parties interested in collaborative of Health, HHS)
Director, Office of Federal Advisory
research to obtain pre-clinical data to be Committee Policy. Dated: July 3, 2007.
used to further develop, evaluate, or Jennifer Spaeth,
[FR Doc. 07–3397 Filed 7–11–07; 8:45 am]
commercialize Caliban/Sdccag1 as a
BILLING CODE 4140–01–M Director, Office of Federal Advisory
novel therapeutic and diagnostic target Committee Policy.
for cancer and other diseases. Please
[FR Doc. 07–3401 Filed 7–11–07; 8:45 am]
contact John D. Hewes, Ph.D. at 301– DEPARTMENT OF HEALTH AND BILLING CODE 4140–01–M
435–3121 or hewesj@mail.nih.gov for HUMAN SERVICES
more information.
Dated: July 5, 2007. National Institutes of Health DEPARTMENT OF HEALTH AND
Steven M. Ferguson, HUMAN SERVICES
National Institute of Diabetes and
Director, Division of Technology Development
and Transfer, Office of Technology Transfer, Digestive and Kidney Disorders; National Institutes of Health
National Institutes of Health. Notice of Closed Meeting
[FR Doc. E7–13542 Filed 7–11–07; 8:45 am] National Institute of Environmental
Pursuant to section 10(d) of the
Health Sciences; Notice of Closed
BILLING CODE 4140–01–P Federal Advisory Committee Act, as
Meeting
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following Pursuant to section 10(d) of the
DEPARTMENT OF HEALTH AND meeting. Federal Advisory Committee Act, as
HUMAN SERVICES The meeting will be closed to the amended (5 U.S.C. Appendix 2), notice
public in accordance with the is hereby given of the following
National Institutes of Health provisions set forth in sections meeting.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., The meeting will be closed to the
National Human Genome Research
as amended. The purpose of this public in accordance with the
Institute; Notice of Closed Meeting
meeting is to evaluate requests for provisions set forth in sections
Pursuant to section 10(d) of the preclinical development resources for 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Federal Advisory Committee Act, as potential new therapeutics for type 1 as amended. The contract proposals and
amended (5 U.S.C. Appendix 2), notice diabetes. The outcome of the evaluation the discussions could disclose
is hereby given of the following will be a decision whether NIDDK confidential trade secrets or commercial
meeting. should support the request and make property such as patentable material,
The meeting will be closed to the available contract resources for and personal information concerning
public in accordance with the development of the potential individuals associated with the contract
provisions set forth in sections therapeutic to improve the treatment or proposals, the disclosure of which
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., prevent the development of type 1 would constitute a clearly unwarranted
rwilkins on PROD1PC63 with NOTICES

as amended. The grant applications and diabetes and its complications. The invasion of personal privacy.
the discussions could disclose research proposals and the discussions Name of Committee: National Institute of
confidential trade secrets or commercial could disclose confidential trade secrets Environmental Health Sciences Special
property such as patentable material, or commercial property such as Emphasis Panel, Scientific Research Analysis
and personal information concerning patentable material, and personal in Bioinformatics and Allied Areas.

VerDate Aug<31>2005 16:42 Jul 11, 2007 Jkt 211001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\12JYN1.SGM 12JYN1